Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;83(2):114-118.
doi: 10.1016/j.ando.2021.12.002. Epub 2021 Dec 16.

Updates on therapy for medullary thyroid cancer in 2021

Affiliations
Review

Updates on therapy for medullary thyroid cancer in 2021

Marie Puerto et al. Ann Endocrinol (Paris). 2022 Apr.

Abstract

Medullary thyroid cancer (MTC) is a rare form of thyroid cancer, frequently linked to a germline or somatic mutation in the RET proto-oncogene. MTC has a good prognosis at the localized stage but prognosis is worse in case of metastases, although there is considerable heterogeneity in progression even in advanced stages. Classical chemotherapy shows little efficacy in this type of cancer. Over the last decade, new effective anti-cancer therapies, in particular multi-targeted tyrosine kinase inhibitors and selective anti-RET tyrosine kinase inhibitors, have changed the management of patients with advanced MTC. The aim of this review is to report the results of studies of these new treatments, and to update the state of knowledge from ongoing studies of treatments such as vectorized internal radiotherapy. In chronic forms, which are incurable but with slow progression, the development of new lines of treatment that can reduce the phenomena of acquired resistance is a major issue.

Keywords: Cancer médullaire de la thyroïde; Cancers de la thyroïde; Medullary thyroid cancer; Multiple endocrine neoplasia; Néoplasies endocriniennes multiples; Thyroid cancer.

PubMed Disclaimer

MeSH terms

Substances

Supplementary concepts